Body fluids

Bio Products Laboratory Announces Launch of ALBUMINEX® 5% and ALBUMINEX® 25% With Supply Immediately Available in the United States

Wednesday, May 27, 2020 - 7:29pm

Use albumin with caution in conditions where hypervolemia and its consequences or hemodilution could represent a special risk to the patient.

Key Points: 
  • Use albumin with caution in conditions where hypervolemia and its consequences or hemodilution could represent a special risk to the patient.
  • No cases of transmission of viral diseases or CJD have ever been identified for ALBUMINEX 5% or ALBUMINEX 25%.
  • BPL USA is part of a global company, Bio Products Laboratory, which boasts a vibrant 60-year heritage in plasma research, technology, and manufacturing.
  • View original content to download multimedia: http://www.prnewswire.com/news-releases/bio-products-laboratory-announce...
    SOURCE Bio Products Laboratory USA Inc.

Leading Thrombosis Specialists Issue Clinical Guidance on the Diagnosis, Prevention and Treatment of Venous Thromboembolism in Hospitalized Patients with COVID-19

Wednesday, May 27, 2020 - 3:08pm

The recommendations are published in a new paper, titled "Clinical Guidance on the Diagnosis, Prevention and Treatment of Venous Thromboembolism in Hospitalized Patients with COVID-19," published on May 27, 2020 in the Journal of Thrombosis and Haemostasis (JTH).

Key Points: 
  • The recommendations are published in a new paper, titled "Clinical Guidance on the Diagnosis, Prevention and Treatment of Venous Thromboembolism in Hospitalized Patients with COVID-19," published on May 27, 2020 in the Journal of Thrombosis and Haemostasis (JTH).
  • The peer-reviewed paper outlines new practical guidance on the prevention and treatment of VTE in hospitalized patients with COVID-19.
  • The recommendations were developed by a multidisciplinary panel of thrombosis experts as a response to widespread clinical reports of unusual, difficult-to-control clotting in COVID-19 patients.
  • For more information on the paper, "Clinical Guidance on the Diagnosis, Prevention and Treatment of Venous Thromboembolism in Hospitalized Patients with COVID-19," visit https://onlinelibrary.wiley.com/doi/abs/10.111/jth.14929.

Headspring and PPTA partner to bring a new global plasma donation system to market

Tuesday, May 26, 2020 - 4:23pm

This new system will have a tangible impact on the plasma collection process and the patients who depend on PPTs.

Key Points: 
  • This new system will have a tangible impact on the plasma collection process and the patients who depend on PPTs.
  • Headspring will replace the legacy system and develop and maintain a single, fully responsive web application system that gives plasma collectors seamless access to two databases: the National Donor Deferral Registry (NDDR) and the Cross Donation Check System (CDCS).
  • "PPTA is looking forward to working with Headspring to develop this advanced system," remarked Joshua Penrod, PPTA Senior Vice President, Source and International Affairs.
  • PPTA also administers standards and programs that help ensure the quality and safety of plasma protein therapies, donors, and patients.

Racing Against Time, Medical Researchers, Life Science Companies and COVID-19 Survivors Launch National Campaign to Drive Blood Plasma Donation

Tuesday, May 26, 2020 - 2:00pm

Coalition members developing an H-Ig include CoVIg-19 Plasma Alliance (CSL Behring, Takeda, ADMA Biologics, Biopharma Plasma, Biotest, BPL, GC Pharma, Octapharma and Sanquin) and Grifols.

Key Points: 
  • Coalition members developing an H-Ig include CoVIg-19 Plasma Alliance (CSL Behring, Takeda, ADMA Biologics, Biopharma Plasma, Biotest, BPL, GC Pharma, Octapharma and Sanquin) and Grifols.
  • Uber Health has contributed 25,000 free, roundtrip Uber rides to and from plasma donor centers for those potentially eligible to donate.
  • "AABB is proud to support blood centers throughout the country that are collecting potentially lifesaving plasma from COVID-19 survivors.
  • We are committed to supporting the survivors who will be participating in this critical campaign to donate their plasma."

Desert Financial Arena Community Blood Drive on May 31 Aims for 350-Plus Donors

Friday, May 22, 2020 - 11:51pm
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20200522005465/en/
    Your donation of blood helps kids like 4-year-old Adelyn, who just had her 66th blood transfusion.
  • (Photo: Business Wire)
    Healthy, eligible donors are invited to the Desert Financial Arena Community Blood Drive Sunday, May 31, from 8:00 a.m. to 2:00 p.m. at Desert Financial Arena on the Arizona State University campus in Tempe.
  • The first 350 donors will receive an ASU/Desert Financial T-shirt in appreciation for giving blood at this crucial time.
  • Vitalant , Arizonas largest nonprofit community blood provider has partnered to host the blood drive.

COLLABORATION BUILDS A COMMUNITY RESOURCE FOR CONVALESCENT PLASMA DONATIONS

Friday, May 8, 2020 - 9:13pm

This convalescent plasma can be used to treat New Mexico patients who are currently suffering from COVID-19 infection with the hope of improving outcomes.

Key Points: 
  • This convalescent plasma can be used to treat New Mexico patients who are currently suffering from COVID-19 infection with the hope of improving outcomes.
  • Dr. Michael Crossey, CEO for TriCore Reference Laboratories, says, TriCore is so proud to be part of this New Mexico collaboration.
  • All the participating institutions were eager to come to the table to benefit the community as a whole.
  • This unique situation allows us to supply this convalescent plasma product back to the patients who need it the most all over the community, regardless of the hospital.

Global Market Insights and Forecasts for the Plasma Therapy Market with Potential Impact of COVID-19 (2020-2024) - ResearchAndMarkets.com

Thursday, May 7, 2020 - 8:33am

The "Global Plasma Therapy Market (Pure PRP, Leukocyte-Rich PRP, Pure PRF, Leukocyte-Rich PRF): Insights & Forecast with Potential Impact of COVID-19 (2020-2024)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Plasma Therapy Market (Pure PRP, Leukocyte-Rich PRP, Pure PRF, Leukocyte-Rich PRF): Insights & Forecast with Potential Impact of COVID-19 (2020-2024)" report has been added to ResearchAndMarkets.com's offering.
  • The global plasma therapy market is expected to reach US$384.94 million in 2024, witnessing growth at a CAGR of 7.24%, over the period 2020-2024.
  • The growth of the market would be challenged by severe side effects of plasma therapy and barriers to implementation.
  • And the global plasma therapy market can be segmented into Hospitals & Clinics and Research Institutes, depending upon the end-user.

Haemonetics 4th Quarter and Fiscal 2020 Earnings Release Available on Investor Relations Website

Tuesday, May 5, 2020 - 11:00am

The Company will host a conference call with investors and analysts to discuss and answer questions about the results at 8 a.m. EDT May 5, 2020.

Key Points: 
  • The Company will host a conference call with investors and analysts to discuss and answer questions about the results at 8 a.m. EDT May 5, 2020.
  • The call can be accessed with the following information:
    U.S. / Canada toll free (877) 848-8880; International (716) 335-9512
    Conference ID required for access: 7365511
    A live webcast of the call can be accessed on Haemonetics' Investor Relations website.
  • Our technology addresses important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services.
  • To learn more about Haemonetics, visit our website at http://www.haemonetics.com .

Cerus Corporation Announces FDA Approval for INTERCEPT Blood System for Plasma with Alternate Plastic Disposable Kits

Monday, May 4, 2020 - 1:30pm

Cerus Corporation (Nasdaq:CERS) announced today FDA regulatory approval for manufacture of INTERCEPT plasma with a new, alternative plastic disposable kit.

Key Points: 
  • Cerus Corporation (Nasdaq:CERS) announced today FDA regulatory approval for manufacture of INTERCEPT plasma with a new, alternative plastic disposable kit.
  • The use of the INTERCEPT Blood System for plasma is a natural extension for our U.S. customers who have already adopted INTERCEPT platelets as the standard of care, continued Greenman.
  • Cerus develops and markets the INTERCEPT Blood System and remains the only company in the blood transfusion space to earn both CE Mark and FDA approval for pathogen reduction of both platelet and plasma components.
  • INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

COVID-19 Antibody Testing Starts For 5,000 Arizona First Responders

Monday, April 27, 2020 - 3:00pm

The tests were made possiblethanks to an $80,000 total donation from Blue Cross Blue Shield of Arizona and Phoenix Suns Charities , which was used to purchase 5,000 test kits for first responders.

Key Points: 
  • The tests were made possiblethanks to an $80,000 total donation from Blue Cross Blue Shield of Arizona and Phoenix Suns Charities , which was used to purchase 5,000 test kits for first responders.
  • "We are extremely grateful for the donation and the continued support from both Phoenix Suns Charities and Blue Cross Blue Shield of Arizona."
  • Additionally, first responders who have COVID-19 antibodies can choose to donate plasma or blood to those fighting COVID-19 infection within the Arizona community.
  • "Today, Phoenix Suns Charities and Blue Cross Blue Shield of Arizona found one way to thank them for their service.